Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.56 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629237 | 0.82 | ALOX5 (0.62) | — | |
| SCHEMBL9630548 | 0.82 | ALOX5 (0.62) | — | |
| SCHEMBL1458790 | 0.80 | — | — | |
| SCHEMBL10053593 | 0.80 | CDC7 (0.51) | CDC7DBF4 | |
| SCHEMBL9628607 | 0.79 | KDM4E (0.58) | — | |
| SCHEMBL9629266 | 0.79 | ALOX5 (0.63) | — | |
| SCHEMBL9629280 | 0.79 | MAPT (0.58) | — | |
| SCHEMBL9629483 | 0.79 | ALOX5 (0.58) | — | |
| SCHEMBL9629255 | 0.79 | KDM4E (0.59) | — | |
| SCHEMBL9630496 | 0.79 | ALOX5 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015022073-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | Grünenthal GmbH (DE) | 2015-02-19 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050341-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050341-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-0457803-A4 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | — | 1991-12-04 | — | — | EP | disclosed |
| EP-0457803-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-11-27 | — | — | EP | disclosed |
| WO-1990009801-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-09-07 | — | — | WO | disclosed |
| WO-1990009381-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-08-23 | — | — | WO | disclosed |
| US-4528291-A | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility | SCHERING CORPORATION (US) | 1985-07-09 | — | — | US | disclosed |
| EP-0097323-A2 | 2-(4-Pyridyl)-thiazole derivatives | SCHERING CORPORATION (US) | 1984-01-04 | — | — | EP | disclosed |
| EP-0000032-B1 | DI- AND TRI-SUBSTITUTED THIAZOLES, THEIR PREPARATION, THEIR USE IN PHARMACEUTICALS AND INTERMEDIATE COMPOUNDS | MERCK & CO. INC. (US) | 1982-05-19 | — | — | EP | disclosed |
| US-4260609-A | Di- and tri- substituted thiazoles | MERCK & CO., INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4259341-A | Di- and tri-substituted thiazoles | MERCK & CO., INC. (US) | 1981-03-31 | — | — | US | disclosed |
| EP-0000032-A1 | Di- and tri-substituted thiazoles, their preparation, their use in pharmaceuticals and intermediate compounds | MERCK & CO. INC. (US) | 1978-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | RYR2, CACNA1E, RYR1 | CDC7 2978/4885DBF4 2241/4885 |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | ORAI1, CACNA1E, RYR2 | CDC7 978/4885DBF4 1869/4885 |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | AADAC, PRRC2C, PRRC2A | CDC7 1170/4885DBF4 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.